Back to Search
Start Over
Modern therapies in atopic dermatitis: biologics and small molecule drugs.
- Source :
-
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2020 Oct; Vol. 18 (10), pp. 1085-1092. Date of Electronic Publication: 2020 Jul 14. - Publication Year :
- 2020
-
Abstract
- Atopic dermatitis (AD) is a frequent, chronic remittent skin disease. The pathophysiology of AD has been increasingly understood within the last years, which may help to identify different endotypes suitable for defined therapies in the future. A patient-oriented therapy considers phenotypical features in addition to genetic and biological markers. The most recent developments in biologics and small-molecule drugs for AD treatment are presented in this article. These molecules, if approved, could change the perspectives for future therapies. Dupilumab is the first approved biologic for the treatment of moderate to severe atopic dermatitis in adolescence and adulthood and has led to a significant improvement in the treatment of this chronic disease. In the present article we present real-life data on the efficacy of dupilumab in adult dermatitis patients. We also discuss other data relevant to the use of dupilumab, and address open questions important for the standard care of atopic dermatitis patients.<br /> (© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.)
Details
- Language :
- English
- ISSN :
- 1610-0387
- Volume :
- 18
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
- Publication Type :
- Academic Journal
- Accession number :
- 32666644
- Full Text :
- https://doi.org/10.1111/ddg.14175